carbachol

Trade name: miostat

Small moleculeapproved

Approved

Sep 28, 1972

Carbachol is a potent cholinergic (parasympathomimetic) agent which produces constriction of the iris and ciliary body resulting in reduction in intraocular pressure. — NCATS

Clinical trial activity

5 trials · 3 clinical orgs · 3 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Aug 1, 2007 (NCT00564408)

Timeline

1970s

Sep 28, 1972
Alcon — Earliest FDA Approval
Sep 28, 1972
Alcon — NDA Organization

1990s

Apr 28, 1995
Novartis — Marketing Organization

2020s

Jan 1, 2021
Earliest Phase 2 Sponsor(trial)
Jan 1, 2022
Earliest Phase 3 Sponsor(trial)

Indications

Approved for

Studied for

Presbyopia · Phase 3

Mechanism of action

Muscarinic acetylcholine receptor M3AGONIST
CHRM3 agonist
Indicated for miosis, M3 likely involved (main form in iris)
- Muscarinic acetylcholine receptor M3 (CHRM3) ↗

Combination products

yuvezzi
with brimonidine

Approval history

approvedPriority reviewSep 28, 1972

Chemistry & pharmacology

Loading structure…

SMILES

C[N+](C)(C)CCOC(N)=O

Mol. weight: 147.2 g/mol
Lipinski Ro5: Pass
Rule of 3: Yes
Chirality: Achiral Molecule
Inorganic: No
Polymer: No
Delivery: Parenteral
Availability: Prescription Only

Oral

Parenteral

Yes

Topical

Sources

Also known as

2-((aminocarbonyl)oxy)-n,n,n-trimethylethanaminium chloride
2-((aminocarbonyl)oxy)-n,n,n-trimethylethanaminium chloride
2-((aminocarbonyl)oxy)-n,n,n-trimethylethanaminum chloride
2-((aminocarbonyl)oxy)-n,n,n-trimethylethanaminum chloride
(2-carbamoyloxyethyl)trimethylammonium chloride
(2-carbamoyloxyethyl)trimethylammonium chloride
(2-hydroxyethyl)trimethyl ammonium chloride carbamate
(2-hydroxyethyl)trimethyl ammonium chloride carbamate
(2-hydroxyethyl)trimethylammonium chloride carbamate
(2-hydroxyethyl)trimethylammonium chloride carbamate
carbachol
carbachol
carbachol
carbachol
carbachol
carbachol
carbachol
carbachol
carbachol
carbachol
carbachol
carbachol
carbachol chloride
carbachol chloride
carbacholine chloride
carbacholine chloride
carbacholum
carbacholum
carbacol
carbacol
carbaminoylcholine chloride
carbaminoylcholine chloride
carbamoylcholine chloride
carbamoylcholine chloride
carbamylcholine
carbamylcholine
carbastat
carbastat
carbastat
carboptic
choline carbamate chloride
choline carbamate chloride
choline chloride, carbamate
choline chloride, carbamate
choline chlorine carbamate
choline chlorine carbamate
doryl
doryl
isopto carbachol
karbachol
karbachol
karbamoylcholin chlorid
karbamoylcholin chlorid
miostat
miostat
miostat
miostat

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT06948357	Phase 2	Mar 24, 2025	Zhaoke (Guangzhou) Pharmaceutical Limited
NCT05270863	Phase 3	Mar 30, 2022	Visus Therapeutics
NCT05135286	Phase 3	Jan 31, 2022	Visus Therapeutics
NCT04774237	Phase 2	Mar 24, 2021	Visus Therapeutics
NCT00564408	N/A	Aug 1, 2007	University of Copenhagen

Showing 5 of 5 trials

Page 1 / 1

Organizations

Research & Development (3)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Visus Therapeutics	For profit	3	3	2	2021
University of Copenhagen	Academic/Hospital	1	1	1	2007
Zhaoke (Guangzhou) Pharmaceutical Limited	Government	1	1	1	2025

3 organizations

Page 1 / 1

Marketing (3)

Organization	Org type	Relationship	Date
Alcon	For profit	NDA	Sep 28, 1972
Novartis	For profit	MKTG	Apr 28, 1995
Pharmafair	For profit	MKTG	—